This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the Geminis study”, published in Hematology in which APICES has collaborated in study setup, coordination and project management, monitoring, data management, statistical analysis and manuscript. This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank Janssen-Cilag for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.
This study describes the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study